Ⅳ期肺腺癌患者ROS1基因状态与使用培美曲塞联合铂类方案化疗效果的关系  

Relationship between ROS1 gene and efficiency of pemetrexed combined with platinum chemotherapy in patients with stage Ⅳ lung adenocarcinoma

作　　者：陶洁[1] 薛淑萍[2] 马晓梅[3] TAO Jie;XUE Shuping;MA Xiaomei(Ward One,Department of Pulmonary Medicine,Tumor Hospital Affiliated to Xinjiang Medical University,Xinjiang Uygur Autonomous Regin,Urumqi 830011,China;the Second Daytime Ward,Tumor Hospital Affiliated to Xinjiang Medical University,Xinjiang Uygur Autonomous Regin,Urumqi 830011,China;Department of Pathology,Tumor Hospital Affiliated to Xinjiang Medical University,Xinjiang Uygur Autonomous Regin,Urumqi 830011,China)

机构地区：[1]新疆医科大学附属肿瘤医院肺内科一病区,新疆乌鲁木齐830011 [2]新疆医科大学附属肿瘤医院日间二病区,新疆乌鲁木齐830011 [3]新疆医科大学附属肿瘤医院病理科,新疆乌鲁木齐830011

出　　处：《中国医药导报》2022年第11期111-114,142,共5页China Medical Herald

基　　金：新疆维吾尔自治区自然科学基金项目(2018D01C254)。

摘　　要：目的探讨ROS1基因状态在Ⅳ期肺腺癌患者中与使用培美曲塞联合铂类标准两药方案化疗效果的关系。方法收集2015年6月至2018年9月在新疆医科大学附属肿瘤医院确诊并接受治疗的Ⅳ期肺腺癌患者共384例。根据ROS1基因状态将患者分成ROS1阳性组(32例)和ROS1阴性组(352例)。所有患者均进行ROS1基因检测,并均接受培美曲塞联合铂类两药方案化疗,分析在晚期肺腺癌患者中ROS1基因状态与客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)的关系。结果ROS1阳性组ORR、DCR高于ROS1阴性组(P<0.05)。ROS1阳性组生存率高于ROS1阴性组(P<0.05)。ROS1基因是死亡的影响因素(HR=0.590,95%CI:0.403~0.863,P<0.05)。结论Ⅳ期肺腺癌ROS1阳性患者一线接受培美曲塞联合铂类标准化疗效果更好,使PFS时间得到延长。Objective To investigate the relationship between ROS1 gene and efficiency of pemetrexed combined with platinum chemotherapy in patients with stage Ⅳ lung adenocarcinoma.Methods A total of 384 patients with stage Ⅳ lung adenocarcinoma treated in the Tumor Hospital Affiliated to Xinjiang Medical University from June 2015 to September 2018 were collected.According to ROS1 gene status,patients were divided into ROS1 positive group(32 cases)and ROS1 negative group(352 cases).All patients underwent ROS1 gene detection and received Pemetrexed combined with platinum chemotherapy.Relationships between objetive reposnse rate(ORR),disease control rate(DCR),progression free survival(PFS)and ROS1 gene status were analyzed.Results The ORR,DCR of ROS1 positive group were higher than ROS1 negative group(P<0.05).The survival rate of patients in ROS1 positive group was higher than that in ROS1 negative group(P<0.05).ROS1 gene was an influencing factor of death(HR=0.590,95%CI:0.403-0.863,P<0.05).Conclusion The first-line treatment of ROS1 positive patients with stage Ⅳ lung adenocarcinoma with Pemetrexed combined with platinum chemotherapy is better,and the time without disease progression is prolonged.

关 键 词：ROS1 肺癌 培美曲塞 化疗 生存分析 

分 类 号：R734.2[医药卫生—肿瘤]